康希诺：公司正在按计划推进mRNA疫苗用于治疗胶质母细胞瘤以及横纹肌肉瘤等适应症的研发

Group 1 - The company is progressing as planned with the development of mRNA vaccines for treating glioblastoma and rhabdomyosarcoma, with the current progress meeting expectations [1] - Investors are inquiring about the status of the tumor vaccine, indicating interest and anticipation regarding the company's developments [1]